Cranbury FDA Thursday, December 30, 2021 0.00 Neutral

FDA Approves HYDROCODONE BITARTRATE AND ACETAMINOPHEN — Cranbury Pharmaceuticals, LLC

Cranbury Pharmaceuticals, LLC won FDA approval for its ANDA201295 generic of Hydrocodone Bitartrate and Acetaminophen, marking the company's entry into a competitive market that may exert downward pressure on pricing and erode the market share of existing branded formulations.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day